Cardiac Dimensions Stock

cardiacdimensions.comHealthcareFounded: 2001

Cardiac Dimensions is a private biotech firm that specializes in device treatments for cardiac failure, functional mitral regurgitation (FMR), and other structural diseases of the heart. The company has developed a new device called Carillon Therapy, a system of wiring that is placed non-invasively into the heart muscle next to the mitral valve. The device reshapes the mitral valve to reduce leakage and regurgitation. Cardiac Dimensions aims to produce similar devices to treat other structural problems of heart valves.

Register for Details

For more details on financing and valuation for Cardiac Dimensions, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Cardiac Dimensions.

Register Today

Cardiac Dimensions investors also invested in these private companies

Team

Management Team

Rick Wypych
President & Chief Executive Officer
Steven Goldberg, MD, FSCAI
Chief Medical Officer
Bob Calcote
Vice President, Operations & Compliance
Carmelo Mastrandrea
Vice President, Sales
Angie Swenson
Vice President, Clinical
Guenter Haines
Vice Presdient, Therapy Development

Board Members

Renee Ryan
RefleXion Medical
Gregory D. Casciaro
Independent Advisor
Doug Fisher
InterWest Partners
Gerry Brunk, MBA
Lumira Ventures
Kurt Wheeler
Blackstone Life Sciences
Nathan Every
Frazier Healthcare Partners
Jim Fitzsimmons
Tissue Regeneration Systems
Fouad Azzam
Life Sciences Partners

Other companies like Cardiac Dimensions in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B

News

Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System.